


MEDsan® COVID-19 IgM/IgG- Rapid Test
Hybrid
The MEDsan® COVID-19 IgM/IgG Rapid Test Hybrid is a solid phase immunochromatography test for the rapid, qualitative and differential detection of IgG and IgM antibodies against SARS-CoV-2 infected cells in human whole blood, serum or plasma. This test provides only a preliminary test result. Therefore, each reactive sample of the MEDsan®COVID-19 IgM/IgG Rapid Test Hybrid must be confirmed with alternative test methods and clinical findings.

MEDsan® Multiplex (SC2 & Flu A/B) Rapid Test
The detection limit for SARS-CoV-2 is 14.4 TCID50/mL or 10 pg/mL.
The MEDsan® Multiplex (SC2 & Flu A/B) Rapid Test is a solid phase immunochromatographic test for the qualitative and differential in vitro detection of specific Influenza A, Influenza B and SARS-CoV-2 antigens in human nasopharyngeal or oropharyngeal secretions.

MEDsan® SARS-CoV-2 Antigen Rapid Test
The detection limit of the MEDsan® SARS-CoV-2 Antigen Rapid Test is 14.4 TCID50/mL or 10 pg/mL.
The MEDsan® SARS-CoV-2 Antigen Rapid Test is a solid phase immunochromatographic assay for the qualitative in vitro detection of specific antigens of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) in human nasopharyngeal and/or oropharyngeal secretions.